Bristol-Myers Squibb, Teva Settle Litigation Over Paraplatin

Law360, New York (April 27, 2004, 12:00 AM EDT) -- Drug maker Bristol-Myers Squibb and Israeli generic drug maker Teva Pharmaceutic Industries have settled patent litigation related to carboplatin injection, the generic version of cancer treatment Paraplatin.

Under the terms of the settlement, Teva has entered into a supply and distribution agreement with Bristol-Myers Squibb for carboplatin injection (50 mg, 150 mg, 450 mg) and carboplatin aqueous solution injection (50 mg/5 ml, 150 mg/15 ml, and 450 mg/45 ml), according to the companies.

The agreement will allow Teva to begin distributing the Bristol-Myers Squibb products for...
To view the full article, register now.